NCT00276159View on ClinicalTrials.gov

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaNon-Hodgkin's LymphomaHodgkin's LymphomaMultiple MyelomaChronic Lymphocytic Leukemia
Interventions
DRUG

852A

Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Masonic Cancer Center, University of Minnesota

OTHER